D. Critchley

发表

1-substituted phthalazines as probes of the substrate-binding site of mammalian molybdenum hydroxylases.

C. Beedham, D. Rance, S. Bruce, 1990, Biochemical pharmacology.

Substrate specificity of human liver aldehyde oxidase toward substituted quinazolines and phthalazines: a comparison with hepatic enzyme from guinea pig, rabbit, and baboon.

C. Beedham, D. Rance, D. Critchley, 1995, Archives of biochemistry and biophysics.

Species variation in hepatic aldehyde oxidase activity

C. Beedham, D. Rance, S. Bruce, 1987, European Journal of Drug Metabolism and Pharmacokinetics.

Dehydrophenylalanine derivatives as VLA-4 integrin antagonists.

M. Robinson, Richard J. Taylor, A. Shock, 2003, Bioorganic & medicinal chemistry letters.

Pharmacokinetic Drug–Drug Interaction of the Novel Anticancer Agent E7070 and Acenocoumarol

J. Schellens, J. Beijnen, H. D. van den Bongard, 2004, Investigational New Drugs.

Clinical implications of trials investigating drug‐drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs

J. Szaflarski, P. Patsalos, B. Gidal, 2020, Epilepsia.

Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820

J. Wanders, J. Schellens, J. Beijnen, 2009, Investigational New Drugs.

Rufinamide: Clinical pharmacokinetics and concentration–response relationships in patients with epilepsy

E. Perucca, J. Cloyd, E. Fuseau, 2008, Epilepsia.

Subcellular localisation of guinea pig hepatic molybdenum hydroxylases.

C. Beedham, D. Rance, D. Critchley, 1992, Biochemical and biophysical research communications.

Biotransformation of carbazeran in guinea pig: effect of hydralazine pretreatment.

C. Beedham, D. Rance, D. Critchley, 1994, Xenobiotica; the fate of foreign compounds in biological systems.

A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug–Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy

E. Ben-Menachem, B. Gunning, K. VanLandingham, 2020, CNS Drugs.

Comparisons between the effects of 5-HT and dl-fenfluramine on food intake and gastric emptying in the rat

S. Cooper, C. Dourish, J. Francis, 1995, Pharmacology Biochemistry and Behavior.

A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects

D. Critchley, J. Berwaerts, Gilmour Morrison, 2020, Epilepsia.

Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study.

A. Arzimanoglou, A. Satlin, E. Schuck, 2016, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

Investigation of the metabolism of rufinamide and its interaction with valproate.

E. T. Williams, Y. Wong, W. G. Lai, 2011, Drug metabolism letters.

Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist

Allan Fletcher, L. Lanfumey, R. Corradetti, 1995, Behavioural Brain Research.

Effects of the selective 5-HT1A receptor antagonist WAY100135 and its enantiomers on 8-OH-DPAT-induced hyperglycaemia in conscious rats.

C. Dourish, V. C. Middlefell, D. Critchley, 1994, European journal of pharmacology.

The effects of 5-HT and dl-fenfluramine on gastric emptying and food intake in fasted rats

S. Cooper, C. Dourish, J. Francis, 1992, Appetite.

Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison

A. C. Dubbelman, J. Schellens, H. Rosing, 2016, Investigational New Drugs.

Pharmacokinetic Drug-Drug Interaction With Coadministration of Cannabidiol and Everolimus in a Phase 1 Healthy Volunteer Trial.

Cuiping Chen, D. Critchley, J. Berwaerts, 2023, Clinical pharmacology in drug development.

Supporting the recommended paediatric dosing regimen for rufinamide in Lennox–Gastaut syndrome using clinical trial simulation

E. Fuseau, M. Marchand, D. Critchley, 2010, Journal of Pharmacokinetics and Pharmacodynamics.

N-(pyrimidin-4-yl) and N-(pyridin-2-yl) phenylalanine derivatives as VLA-4 integrin antagonists.

David Critchley, M. Robinson, A. Shock, 2002, Bioorganic & medicinal chemistry letters.

A Phase 1 Open‐Label, Fixed‐Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects

D. Critchley, Ching Thai, Bola Tayo, 2021, Clinical pharmacology in drug development.

Discovery and evaluation of N-(triazin-1,3,5-yl) phenylalanine derivatives as VLA-4 integrin antagonists.

David Critchley, M. Robinson, A. Shock, 2002, Bioorganic & medicinal chemistry letters.